Gilead Sciences Insider Sells $432,690 in Stock

Johanna Mercier, a Gilead Sciences insider, sold 3,000 shares of the company's stock.

Mar. 19, 2026 at 9:13am

Got story updates? Submit your updates here. ›

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 3,000 shares of the company's stock on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, Mercier directly owned 131,779 shares in the company, valued at approximately $19,006,485.17.

Why it matters

Insider transactions, such as stock sales, can provide insights into a company's performance and the views of its leadership. Mercier's sale represents a 2.23% decrease in her ownership stake in Gilead Sciences, which is one of the world's leading biopharmaceutical companies focused on antiviral therapies and other high-need medical areas.

The details

The sale was disclosed in a document filed with the Securities & Exchange Commission. Gilead Sciences has a market capitalization of $175.40 billion and its stock has traded in a range of $93.37 to $157.29 over the past year. The company recently increased its quarterly dividend to $0.82 per share.

  • Mercier sold the 3,000 shares on Monday, March 16th, 2026.

The players

Johanna Mercier

An insider at Gilead Sciences, Inc. who sold 3,000 shares of the company's stock.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need, including antiviral therapies, oncology, cell therapy and inflammatory diseases.

Got photos? Submit your photos here. ›

The takeaway

This insider sale by Johanna Mercier provides a data point on Gilead Sciences' stock performance and the views of its leadership, though the reasons behind the sale are not explicitly stated. Investors will likely continue to monitor Gilead's financial results, pipeline progress, and any further insider transactions.